Sygnature Discovery is a leading United Kingdom-based provider of integrated drug discovery services. Key areas of expertise include medicinal and synthetic chemistry, computational chemistry, bioscience (in vitro biology and screening) and DMPK. The company was founded in 2004 in BioCity (www.biocity.co.uk) and occupies modern, purpose-built laboratories and offices near to the centre of Nottingham. There is also a site in Alderley Park. Our clients are located worldwide, and range from small biotechnology companies to medium-sized pharmaceutical companies.
Sygnature's team of over 350 industry-experienced scientists add considerable value to client's drug discovery activities by undertaking complete drug discovery programmes and key elements of the drug discovery process, such as hit finding, hit-to-lead and lead optimisation. Sygnature's scientists provide considerable intellectual input into client projects; thereby generating novel intellectual property. Pharmaceutical candidates discovered at Sygnature for clients are currently undergoing clinical trials in a variety of diseases with unmet medical need.
Website: Sygnature Discovery